Literature DB >> 15043163

Enhanced DNA-directed effects of FdUMP[10] compared to 5FU.

William H Gmeiner1, Eric Trump, Cui Wei.   

Abstract

FdUMP[N] molecules and conjugates are much more effective at inhibiting the proliferation of human tumor cells than is the widely used anticancer drug 5-fluorouracil (5FU). We have evaluated the inhibition of thymidylate synthase (TS), the extent of DNA damage, cell cycle arrest, and the induction of apoptosis by FdUMP[10] and 5FU in the human colorectal cancer cell line HT29. The magnitude and duration of TS inhibition following exposure of HT29 cells to FdUMP[10] at 1 x 10(-8) M was greater than that which occurred following exposure of these cells to 5FU at 1 x 10(-6) M. FdUMP[10] exposure also resulted in much more extensive DNA damage to HT29 cells than occurred following exposure to 100-fold higher concentrations of 5FU. Although exposure of HT29 cells to both drugs resulted in S-phase arrest, more complete accumulation of cells in S-phase was achieved following FdUMP[10] exposure at much lower drug concentrations. FdUMP[10] was also much more effective at inducing apoptosis in HT29 cells than was 5FU. The results are consistent with FdUMP[10] being much more efficient that 5FU at inducing DNA damage that results in apoptotic cell death in colon cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15043163     DOI: 10.1081/ncn-120028336

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  15 in total

1.  Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties.

Authors:  William H Gmeiner; Anthony Dominijanni; Alex O Haber; Lais P Ghiraldeli; David L Caudell; Ralph D'Agostino; Boris C Pasche; Thomas L Smith; Zhiyong Deng; Sezgin Kiren; Chinnadurai Mani; Komaraiah Palle; Jonathan R Brody
Journal:  Mol Cancer Ther       Date:  2020-12-23       Impact factor: 6.261

Review 2.  The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.

Authors:  William H Gmeiner; Waldemar Debinski; Carol Milligan; David Caudell; Timothy S Pardee
Journal:  Future Oncol       Date:  2016-06-09       Impact factor: 3.404

3.  Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.

Authors:  Timothy S Pardee; Evan Gomes; Jamie Jennings-Gee; David Caudell; William H Gmeiner
Journal:  Blood       Date:  2012-02-23       Impact factor: 22.113

4.  The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2.

Authors:  William H Gmeiner; Olcay Boyacioglu; Christopher H Stuart; Jamie Jennings-Gee; K C Balaji
Journal:  Prostate       Date:  2014-11-18       Impact factor: 4.104

5.  Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.

Authors:  William H Gmeiner; William C Reinhold; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2010-12       Impact factor: 6.261

6.  Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.

Authors:  William H Gmeiner; Jamie Jennings-Gee; Christopher H Stuart; Timothy S Pardee
Journal:  Leuk Res       Date:  2014-11-29       Impact factor: 3.156

7.  Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines.

Authors:  Ivana Grivicich; Andréa Regner; Caroline Zanoni; Larissa Procópio Correa; Geraldo Pereira Jotz; João Antônio Pêgas Henriques; Gilberto Schwartsmann; Adriana Brondani da Rocha
Journal:  Int J Colorectal Dis       Date:  2007-03-28       Impact factor: 2.571

8.  Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity.

Authors:  Jamie Jennings-Gee; Timothy S Pardee; William H Gmeiner
Journal:  Exp Hematol       Date:  2012-10-17       Impact factor: 3.084

9.  AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition.

Authors:  William H Gmeiner; Jonathan R Brody; Alex O Haber; Aditi Jain; Chinnadurai Mani; Avinoam Nevler; Lebaron C Agostini; Talia Golan; Komaraiah Palle; Charles J Yeo
Journal:  Mol Cancer Res       Date:  2021-02-16       Impact factor: 6.333

10.  Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.

Authors:  Irene V Bijnsdorp; Reto A Schwendener; Herbert Schott; Iduna Fichtner; Kees Smid; Adrie C Laan; Sarah Schott; Nienke Losekoot; Richard J Honeywell; Godefridus J Peters
Journal:  Invest New Drugs       Date:  2009-12-03       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.